Diligence memo · auto-generated · as of July 2, 2026
Yuko Project, LLC
Yuko Project, LLC looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Yuko Project, LLC operates in Biotechnology, based in NASHVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Yuko Project, LLC has raised $10M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2025-08-26.
Most recent recorded round closed around 2025-08-26.
Valuation (modeled)modeled
Provath models Yuko Project, LLC at approximately $30M (range $11M–$50M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.92× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Last raise 10 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 56% of Biotechnology peers (4293 compared).
Modeled value ranks above 35% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.